

**To Art. 33, Par. 1 of Ordinance № 2 from 17.09.2003  
And Regulation (EU) 596/2014 of the European  
Parliament and of the Council of 16 April 2014**

*1.1. No change in the persons controlling the Company.*

*1.6. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.*

*1.7. No acquisition, use or disposition of high-value assets under art. 114, par. 1, item 1 of POSA*

*1.8. No decision on conclusion, termination and cancellation of joint venture agreements.*

On 04.04.2017 a contract was signed for the sale of the Group's participation through the subsidiary SEA Briz, Latvia in the amount of 50% in the joint venture OOO Vivaton Plus, Belarus. Under the terms of the contract, the transaction should be finalized within 30 days of the date of its conclusion.

*1.10. Change in the Company's auditors.*

The General Meeting of Shareholders of Sopharma AD selected the auditing company Baker Tilly Clitou and Partners Ltd. as a registered auditor of the Company for 2017. The reason for change of the previous external auditor "AFA" OOD is compliance with the requirements of art.65, par.3 of the Independent Financial Act Audit.

**1.30. No initiation or termination of a court or arbitration proceedings relating to claims or liabilities of the company or its subsidiary, with the price of the claim at least 10% of the company's equity.**

**1.31. Purchase, sale or pledge of shares in companies of the issuer or its subsidiary**

The structure of the Group includes Sopharma AD as a parent company and the subsidiaries stated below:

Subsidiaries	Jan-June 2017In terest	Jan-June 2016I nterest	Date of acquisition of control	Date of disposal of control
Companies in Bulgaria	%	%		
Sopharma Trading AD*	72.61	72.58	08.06.2006	
Pharmalogistica AD	89.39	84.93	15.08.2002	
Electroncommerce EOOD	100	100	09.08.2005	
Biopharm Engineering AD	97.15	97.15	10.03.2006	
Sopharma Buildings REIT	40.38	40.39	04.08.2008	
Momina Krepost AD	93.54	93.54	01.01.2008	
Unipharm AD *	96.68	77.89	27.10.2010	
Phyto Palauzovo AD	95	95	21.09.2012	
Sopharmacy EOOD**	72.61	72.58	19.01.2015	
Sopharmacy 2 EOOD**	72.61	72.58	05.06.2015	
Sopharmacy 3 EOOD**	72.61	72.58	02.12.2015	
Sopharmacy 4 EOOD**	72.61	72.58	29.02.2016	

Sopharmacy 5 EOOD**	72.61	72.58	01.03.2016	
Sopharmacy 6 EOOD**	72.61	72.58	03.12.2015	
Sopharmacy 7 EOOD**	72.61	-	15.03.2017	
Sopharmacy 8 EOOD**	72.61	-	27.06.2017	
Medica AD	97.96	97.96	26.10.2015	
Medica-Zdrave EOOD **	-	97.96	26.10.2015	22.02.2017
Veta Pharma AD	68.05	68.05	11.11.2016	
* efficient percentage of interest				
** indirect interest	-			

Subsidiaries	Jan-June 2017 Interest %	Jan-June 2016 Interes t %	Date of acquisition of control	Date of disposal of control
Companies abroad				
SIA Briz	66.13	66.13	10.11.2009	
SOOO Brititrade **	52.90	52.90	10.11.2009	
PAO Vitamini	99.56	99.56	18.01.2008	
Sopharma Warsaw SP. Z.O.O.	100	100	23.11.2010	
Sopharma Trading d.o.o. Belgrade**	72.61	72.58	05.06.2015	
Sopharma Poland Z.O.O. – in liquidation	60	60	16.10.2003	
OOO Tabina **	62.82	62.82	08.04.2011	
SOOO Brizpharm **	33.40	46.26	20.12.2012	
ODO Alean **	62.96	62.96	07.02.2013	
OOO Sopharma Ukraine	100	100	07.08.2012	
OOO Farmacevt Plus **	33.73	42.98	31.05.2013	
UAB TBS Pharma**	33.73	33.73	01.03.2013	
ODO Vestpharm **	52.90	62.96	04.07.2013	
ODO BelAgroMed **	52.90	62.96	30.07.2013	
TOO Sopharma Kazakhstan	100	100	06.11.2014	
OOO Danapharm**	48.94	48.94	28.02.2015	
OOO Galenapharm**	48.94	48.94	28.02.2015	
ODO Medjel**	48.94	48.94	28.02.2015	
ODO Alenpharm-plus**	48.94	48.94	30.06.2015	
OOO Farmatea**	17.85	22.39	30.11.2015	
OOO Mobil Line**	47.61	48.94	16.02.2016	
ODO SalusLine**	48.94	48.74	18.11.2016	
Rap Pharma International OOD	51	-	14.04.2017	
ZAO Interfarm**	59.52	-	26.04.2017	

\* efficient percentage of interest

\*\* indirect interest

- Unipharm AD is a subsidiary to Sopharma AD, the control thereon being acquired and exercised through the direct participation of the parent company in the ownership of Unipharm AD with 96.68%;
- Sopharma Trading AD is a subsidiary of Sopharma AD, the control thereon being acquired and exercised through the direct participation of the parent company in the ownership of Sopharma Trading AD with 72.16% and the indirect participation of the parent company with 0.42% through the subsidiary Medica AD holding 0.43% of the capital of Sopharma Trading AD and 0.03% through the subsidiary Unipharm AD holding 0.03% of the capital of Sopharma Trading AD;
- Sopharma Buildings REIT is a subsidiary by virtue of a written agreement for control concluded between Sopharma AD and other shareholders;
- Phyto Palauzovo is a direct subsidiary after the merger of Bulgarian Rose-Sevtopolis AD into Sopharma AD (as from 1 January January-June 2016);
- Sopharmacy EOOD is a subsidiary of Sopharma Trading AD whereas the latter holds 100% of the capital of Sopharmacy EOOD;
- Sopharmacy 2 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital of Sopharmacy 2 EOOD;
- Sopharmacy 3 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital of Sopharmacy 3 EOOD;
- Sopharmacy 4 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital of Sopharmacy 4 EOOD;
- Sopharmacy 5 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital of Sopharmacy 5 EOOD;
- Sopharmacy 6 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital of Sopharmacy 6 EOOD;
- Sopharmacy 7 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital Sopharmacy 7 EOOD;
- Sopharmacy 8 EOOD is a subsidiary of Sopharmacy EOOD whereas the latter holds 100% of the capital Sopharmacy 7 EOOD;
- Sopharma Trading d.o.o. Belgrade is a subsidiary of Sopharma Trading AD whereas the latter holds 100% of the capital of Sopharma Trading d.o.o. Belgrade;
- Medica-Zdrave EOOD (in liquidation) is a subsidiary of Medica AD whereas the latter holds 100% of the capital of Medica-Zdrave EOOD;
- SOOO Brititrade, Belarus, is a subsidiary of SIA Briz, Latvia, whereas the latter holds 80% of the capital of SOOO Brititrade;
- OOO Tabina, Belarus, is a subsidiary through SIA Briz, Latvia, whereas the latter holds 95% of the capital of OOO Tabina;

- SOOO Brizpharm, Belarus, is a subsidiary through SIA Briz, Latvia and its subsidiary OOO Pharmacevt plus, Belarus – SIA Briz holds 12.27% of the capital of SOOO Brizpharm and OOO Pharmacevt Plus – 74.98% of the capital of SOOO Brizpharm;
- ODO Alean, Belarus, is a subsidiary through Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 76% and SOOO Brititrade holds 24% of the capital of ODO Alean;
- OOO Farmacevt Plus, Belarus, is a subsidiary through SIA Briz, Latvia, whereas the latter holds 51% of the capital of OOO Farmacevt Plus;
- UAB TBS Pharma, Lithuania, is a subsidiary through SIA Briz, Latvia, whereas the latter holds 51% of the capital of UAB TBS Pharma;
- ODO Vestpharm, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 100% and SOOO Brititrade holds 24% of the capital of ODO Vestpharm;
- ODO BelAgroMed, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 100% and SOOO Brititrade holds 24% of the capital of ODO BelAgroMed;
- ODO Danapharm, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 10% and SOOO Brititrade holds 80% of the capital of ODO Danapharm;
- ODO Galenapharm, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 10% and SOOO Brititrade holds 80% of the capital of ODO Galenapharm;
- ODO Medjel, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 10% and SOOO Brititrade holds 80% of the capital of ODO Medjel;
- ODO Alenpharm-plus, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus, whereas SIA Briz holds 10% and SOOO Brititrade holds 80% of the capital of ODO Alenpharm-plus;
- ODO Farmatea, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary OOO Farmacevt Plus, Belarus, whereas SIA Briz holds 2% and OOO Farmacevt Plus holds 49% of the capital of ODO Farmatea;
- ODO Mobil Line, Belarus, is a subsidiary through SOOO Brititrade, Belarus, whereas SIA Briz holds 10% and SOOO Brititrade holds 90% of the capital of ODO Mobil Line;
- ODO SalusLine, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus - SIA Briz holds 10%, SOOO Brititrade holds 80%.
- ZAO Interfarm, Belarus, is a subsidiary through SIA Briz, Latvia, and its subsidiary SOOO Brititrade, Belarus - SIA Briz holds 50%, SOOO Brititrade holds 50%.

## AVAILABLE-FOR-SALE INVESTMENTS

The carrying amount of the investments by company is as follows:

	<i>Country</i>	<i>Jan-June 2017 BGN '000</i>	<i>Interes t %</i>	<i>Jan-June 2016 BGN '000</i>	<i>Interes t %</i>
Lavena AD	Bulgaria	2,898	11.34	2,883	11.29
Olainfarm AD	Latvia	2,033	0.77	1,796	0.77
Achieve Life Sciences Inc.	USA	290	4.70	290	5.00
OOO Pharmico	Belarus	172	2.00	172	2.00
Hydroizomat AD	Bulgaria	168	12.45	131	10.65
ODO DKM-Pharm	Belarus	100	2.00	100	2.00
Sopharma Properties REIT	Bulgaria	76	0.07	64	0.07
OOO Set Aptek	Belarus	70	2.00	70	2.00
Todorov AD	Bulgaria	66	7.14	37	4.98
BTF Expat Bulgaria	Bulgaria	-	-	82	0.32
Other		97		96	
<b>Total</b>		<b>5,970</b>		<b>5,721</b>	

The other available-for-sale investments as at 30 June 2017, amounting to BGN 97 thousand (31 December 2016: BGN 96 thousand), include a number of minority interests of the Group in the capital of five companies (31 December 2016: five companies).

The investments in Extab Pharma Inc., USA, and all other companies in Belarus are valued and presented in the consolidated financial statements at acquisition cost.

### ***1.34. Other circumstances which the company believes could be relevant for investors in deciding to acquire, sell or continue to hold publicly traded securities:***

All circumstances, that the company considers important for the investors while making the decision to acquire, sell or continue to possess shares are revealed in public, are included in the consolidated statement for the first quarter of 2017.